In addition, we observed genotype-specific differences in response to drug treatment as resmetirom demonstrated greater efficacy in the PNPLA3 wild-type CC LAMPS than that in the GG variant in the reduction of steatosis, stellate cell activation, and the secretion of marker COL1A1 (Table 3). Here, PNPLA3 is linked to steatosis.